Imezemic 500 Tablet

Imezemic 500 is typically prescribed as monotherapy or as an adjunct to other antidiabetic agents when glycemic control is inadequate with diet and exercise alone. Clinical studies have demonstrated that Imeglimin effectively reduces fasting plasma glucose and HbA1c levels, contributing to improved glycemic control with a favorable safety profile. The medication is generally well tolerated, with the most common adverse effects being mild gastrointestinal disturbances such as nausea and diarrhea.

Dose adjustments may be necessary in patients with renal impairment, and it is contraindicated in individuals with severe renal dysfunction. Regular monitoring of blood glucose and renal function is recommended during therapy. Imezemic 500 should be used under medical supervision, with adherence to prescribed dosage and lifestyle modifications to optimize therapeutic outcomes in patients with type 2 diabetes.